Gregory T Robertson

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1032568/gregory-t-robertson-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 papers	5,223 citations	24 h-index	52 g-index
52 ext. papers	5,909 ext. citations	7.3 avg, IF	4.8 L-index

#	Paper	IF	Citations
48	Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0219221	5.9	2
47	Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0231021	5.9	0
46	Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. *Nature Communications*, **2021**, 12, 2899	17.4	10
45	The Tuberculosis Drug Accelerator at year 10: what have we learned?. *Nature Medicine*, **2021**, 27, 1333-1337	36.5	7
44	Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0058321	5.9	4
43	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0174420	5.9	1
42	1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in. *Journal of Medicinal Chemistry*, **2021**, 64, 12790-12807	8.3	6
41	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. *ACS Infectious Diseases*, **2021**, 7, 2850-2863	5.5	0
40	Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity. *ACS Infectious Diseases*, **2020**, 6, 1951-1964	5.5	10
39	Allosteric inhibitors of Mycobacterium tuberculosis tryptophan synthase. *Protein Science*, **2020**, 29, 779-788	6.8	12
38	Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. *Scientific Reports*, **2020**, 10, 6047	4.9	6
37	Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
36	Discovery of a cofactor-independent inhibitor of InhA. *Life Science Alliance*, **2018**, 1, e201800025	5.8	18
35	Development of a Novel Lead that Targets M.tuberculosis Polyketide Synthase 13. *Cell*, **2017**, 170, 249-259.e25	36.2	88
34	Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. *ACS Infectious Diseases*, **2017**, 3, 72-88	5.5	25
33	Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 770-777	5.1	19
32	Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase. *Journal of Medicinal Chemistry*, **2014**, 57, 8947-59	8.3	18

31	FTT0831c/FTL_0325 contributes to Francisella tularensis cell division, maintenance of cell shape, and structural integrity. *Infection and Immunity*, **2014**, 82, 2935-48	3.7	14
30	IglE is an outer membrane-associated lipoprotein essential for intracellular survival and murine virulence of type A Francisella tularensis. *Infection and Immunity*, **2013**, 81, 4026-40	3.7	21
29	Method for the isolation of Francisella tularensis outer membranes. *Journal of Visualized Experiments*, **2010**,	1.6	8
28	Bacterial and fungal biofilm infections. *Annual Review of Medicine*, **2008**, 59, 415-28	17.4	312
27	In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2324-34	5.9	44
26	In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2313-23	5.9	51
25	New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 522-6	2.9	33
24	A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. *Journal of Bacteriology*, **2007**, 189, 6870-81	3.5	37
23	Role of HdeA in acid resistance and virulence in Brucella abortus 2308. *Veterinary Microbiology*, **2005**, 107, 307-12	3.3	34
22	Use of an efflux-deficient streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 4781-3	5.9	57
21	The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. *Infection and Immunity*, **2005**, 73, 2873-80	3.7	103
20	Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. *Journal of Bacteriology*, **2003**, 185, 359-70	3.5	112
19	Brucella stationary-phase gene expression and virulence. *Annual Review of Microbiology*, **2003**, 57, 57-76	17.5	67
18	Constitutive expression of PcsB suppresses the requirement for the essential VicR (YycF) response regulator in Streptococcus pneumoniae R6. *Molecular Microbiology*, **2003**, 50, 1647-63	4.1	115
17	Essentiality of clpX, but not clpP, clpL, clpC, or clpE, in Streptococcus pneumoniae R6. *Journal of Bacteriology*, **2003**, 185, 2961-6	3.5	31
16	Seeking a niche: putative contributions of the hfq and bacA gene products to the successful adaptation of the brucellae to their intracellular home. *Veterinary Microbiology*, **2002**, 90, 349-63	3.3	28
15	Major histocompatibility complex class I and II expression on macrophages containing a virulent strain of Brucella abortus measured using green fluorescent protein-expressing brucellae and flow cytometry. *FEMS Immunology and Medical Microbiology*, **2002**, 33, 191-200		19
14	Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence. *Journal of Bacteriology*, **2002**, 184, 3508-20	3.5	121

13	Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae. *Journal of Bacteriology*, **2002**, 184, 6987-7000	3.5	38
12	Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery. *Current Opinion in Microbiology*, **2002**, 5, 338-42	7.9	23
11	Genome of the bacterium Streptococcus pneumoniae strain R6. *Journal of Bacteriology*, **2001**, 183, 5709-17	3.5	612
10	The Brucella abortus Lon functions as a generalized stress response protease and is required for wild-type virulence in BALB/c mice. *Molecular Microbiology*, **2000**, 35, 577-88	4.1	71
9	The Brucella abortus CcrM DNA methyltransferase is essential for viability, and its overexpression attenuates intracellular replication in murine macrophages. *Journal of Bacteriology*, **2000**, 182, 3482-9	3.5	107
8	The Brucella abortus host factor I (HF-I) protein contributes to stress resistance during stationary phase and is a major determinant of virulence in mice. *Molecular Microbiology*, **1999**, 34, 690-700	4.1	164
7	Cloning and nucleotide sequence analysis of a Brucella abortus gene encoding an 18 kDa immunoreactive protein. *Microbial Pathogenesis*, **1997**, 22, 241-6	3.8	9
6	A Brucella melitensis high-temperature-requirement A (htrA) deletion mutant is attenuated in goats and protects against abortion. *Research in Veterinary Science*, **1997**, 63, 165-7	2.5	26
5	Behaviour of a high-temperature-requirement A (HtrA) deletion mutant of Brucella abortus in goats. *Research in Veterinary Science*, **1996**, 60, 48-50	2.5	10
4	In vitro and in vivo phenotypes resulting from deletion of the high temperature requirement A (htrA) gene from the bovine vaccine strain Brucella abortus S19. *Veterinary Microbiology*, **1996**, 49, 197-207	3.3	10
3	In vivo and in vitro stability of the broad-host-range cloning vector pBBR1MCS in six Brucella species. *Plasmid*, **1995**, 33, 51-7	3.3	60
2	Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. *Gene*, **1995**, 166, 175-6	3.8	2652
1	Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments		1